Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 3
1993 1
1995 1
1996 3
1998 1
2001 1
2002 2
2003 2
2004 3
2005 3
2006 2
2007 2
2008 4
2009 8
2010 4
2011 4
2012 4
2014 1
2015 2
2016 1
2017 2
2018 2
2019 4
2020 5
2023 1
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

62 results

Results by year

Filters applied: . Clear all
Page 1
Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid-sparing effect.
Chen DM, Odueyungbo A, Csinady E, Gearhart L, Lehane P, Cheu M, Maho-Vaillant M, Prost-Squarcioni C, Hebert V, Houivet E, Calbo S, Caillot F, Golinski ML, Labeille B, Picard-Dahan C, Paul C, Richard MA, Bouaziz JD, Duvert-Lehembre S, Bernard P, Caux F, Alexandre M, Ingen-Housz-Oro S, Vabres P, Delaporte E, Quereux G, Dupuy A, Debarbieux S, Avenel-Audran M, D'Incan M, Bedane C, Bénéton N, Jullien D, Dupin N, Misery L, Machet L, Beylot-Barry M, Dereure O, Sassolas B, Benichou J, Musette P, Joly P; French Study Group on Autoimmune Bullous Diseases. Chen DM, et al. Among authors: picard dahan c. Br J Dermatol. 2020 May;182(5):1111-1119. doi: 10.1111/bjd.18482. Epub 2019 Nov 28. Br J Dermatol. 2020. PMID: 31487383 Free PMC article. Clinical Trial.
First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial.
Joly P, Maho-Vaillant M, Prost-Squarcioni C, Hebert V, Houivet E, Calbo S, Caillot F, Golinski ML, Labeille B, Picard-Dahan C, Paul C, Richard MA, Bouaziz JD, Duvert-Lehembre S, Bernard P, Caux F, Alexandre M, Ingen-Housz-Oro S, Vabres P, Delaporte E, Quereux G, Dupuy A, Debarbieux S, Avenel-Audran M, D'Incan M, Bedane C, Bénéton N, Jullien D, Dupin N, Misery L, Machet L, Beylot-Barry M, Dereure O, Sassolas B, Vermeulin T, Benichou J, Musette P; French study group on autoimmune bullous skin diseases. Joly P, et al. Among authors: picard dahan c. Lancet. 2017 May 20;389(10083):2031-2040. doi: 10.1016/S0140-6736(17)30070-3. Epub 2017 Mar 22. Lancet. 2017. PMID: 28342637 Clinical Trial.
Efficacy and safety of dupilumab in bullous pemphigoid: a retrospective multicentric study of 36 patients.
Moghadam P, Tancrede E, Bouaziz JD, Kallout J, Bedane C, Begon E, Bourgault-Villada I, Calugareanu A, Dereure O, Jendoubi F, Pham-Ledard A, Ingen-Housz-Oro S, Picard-Dahan C, Viguier M, Mahevas T, Jachiet M, Charvet E, Cassius C, Alexandre M, Lepelletier C. Moghadam P, et al. Among authors: picard dahan c. Br J Dermatol. 2023 Jul 17;189(2):244-246. doi: 10.1093/bjd/ljad136. Br J Dermatol. 2023. PMID: 37155583 No abstract available.
Large International Validation of ABSIS and PDAI Pemphigus Severity Scores.
Hébert V, Boulard C, Houivet E, Duvert Lehembre S, Borradori L, Della Torre R, Feliciani C, Fania L, Zambruno G, Camaioni DB, Didona B, Marinovic B, Schmidt E, Schumacher N, Hünefeld C, Schanz S, Kern JS, Hofmann S, Bouyeure AC, Picard-Dahan C, Prost-Squarcioni C, Caux F, Alexandre M, Ingen-Housz-Oro S, Bagot M, Tancrede-Bohin E, Bouaziz JD, Franck N, Vabres P, Labeille B, Richard MA, Delaporte E, Dupuy A, D'Incan M, Quereux G, Skowro F, Paul C, Livideanu CB, Beylot-Barry M, Doutre MS, Avenel-Audran M, Bedane C, Bernard P, Machet L, Maillard H, Jullien D, Debarbieux S, Sassolas B, Misery L, Abasq C, Dereure O, Lagoutte P, Ferranti V, Werth VP, Murrell DF, Hertl M, Benichou J, Joly P; French Study Group on Autoimmune Bullous Skin Diseases; Autoimmune Bullous Skin Disease Task Force of the European Academy of Dermatology and Venereology. Hébert V, et al. Among authors: picard dahan c. J Invest Dermatol. 2019 Jan;139(1):31-37. doi: 10.1016/j.jid.2018.04.042. Epub 2018 Oct 6. J Invest Dermatol. 2019. PMID: 30301637 Free article. Review.
Omalizumab in the treatment of bullous pemphigoid resistant to first-line therapy: a French national multicentre retrospective study of 100 patients.
Chebani R, Lombart F, Chaby G, Dadban A, Debarbieux S, Viguier MA, Ingen-Housz-Oro S, Pham-Ledard A, Bedane CR, Picard-Dahan C, Berthin C, Dereure O, Konstantinou MP, Castel M, Jouen F, Joly P, Seta V, Duvert-Lehembre S, Le Roux C, Quereux G, Sassolas B, Brenaut E, Sin C, Richard MA, Bérard F, Giusti D, Belmondo T, Gille T, Caux F, Prost-Squarcioni C, Grootenboer-Mignot S, Alexandre M; French Study Group on Autoimmune Bullous Diseases. Chebani R, et al. Among authors: picard dahan c. Br J Dermatol. 2024 Jan 23;190(2):258-265. doi: 10.1093/bjd/ljad369. Br J Dermatol. 2024. PMID: 37792727
Sustained Remission Without Corticosteroids Among Patients With Pemphigus Who Had Rituximab as First-Line Therapy: Follow-Up of the Ritux 3 Trial.
Tedbirt B, Maho-Vaillant M, Houivet E, Mignard C, Golinski ML, Calbo S, Prost-Squarcioni C, Labeille B, Picard-Dahan C, Chaby G, Richard MA, Tancrede-Bohin E, Duvert-Lehembre S, Delaporte E, Bernard P, Caux F, Alexandre M, Musette P, Ingen-Housz-Oro S, Vabres P, Quereux G, Dupuy A, Debarbieux S, Avenel-Audran M, D'Incan M, Bédane C, Bénéton N, Jullien D, Dupin N, Misery L, Machet L, Beylot-Barry M, Dereure O, Sassolas B, Benichou J, Joly P, Hébert V; French Reference Center for Autoimmune Blistering Diseases MALIBUL. Tedbirt B, et al. Among authors: picard dahan c. JAMA Dermatol. 2024 Mar 1;160(3):290-296. doi: 10.1001/jamadermatol.2023.5679. JAMA Dermatol. 2024. PMID: 38265821 Clinical Trial.
[Update of the French recommendations for the management of pemphigus].
Jelti L, Prost-Squarcioni C, Ingen-Housz-Oro S, Caux F, Bernard P, Bedane C, Alexandre M, Dereure O, Quereux G, Le Bidre E, Plée J, Picard-Dahan C, Le Roux-Villet C, Duvert-Lehembre S, Richard MA, Delaporte E, Debarbieux S, Jullien D, D'Incan M, Konstantinou MP, Bouaziz JD, Tancrède-Bohin E, Doutre MS, Bourgault Villada I, Cordel N, Sassolas B, Viguier MA, Mellottée B, Jouen F, Hebert V, Joly P; Centre de référence des maladies bulleuses auto-immunes (MALIBUL); Groupe Bulles de la SFD et la Filière des maladies rares dermatologiques (FIMARAD). Jelti L, et al. Among authors: picard dahan c. Ann Dermatol Venereol. 2019 Apr;146(4):279-286. doi: 10.1016/j.annder.2019.01.018. Epub 2019 Mar 29. Ann Dermatol Venereol. 2019. PMID: 30929874 French. No abstract available.
[Bacillary angiomatosis].
Picard-Dahan C, Robert-Knebelmann C, Belaich S. Picard-Dahan C, et al. Ann Pathol. 1992;12(4-5):284-90. Ann Pathol. 1992. PMID: 1466685 Review. French. No abstract available.
[Bacillary angiomatosis].
Robert C, Picard-Dahan C, Belaich S. Robert C, et al. Among authors: picard dahan c. Presse Med. 1992 Oct 17;21(34):1625-30. Presse Med. 1992. PMID: 1470625 Review. French.
New insights in COVID-19-associated chilblains: A comparative study with chilblain lupus erythematosus.
Battesti G, El Khalifa J, Abdelhedi N, Ferre V, Bouscarat F, Picard-Dahan C, Brunet-Possenti F, Collin G, Lavaud J, Le Bozec P, Rousselot M, Tournier A, Lheure C, Couvelard A, Hacein-Bey-Abina S, Abina AM, Charpentier C, Mignot S, Nicaise P, Descamps D, Deschamps L, Descamps V. Battesti G, et al. Among authors: picard dahan c. J Am Acad Dermatol. 2020 Oct;83(4):1219-1222. doi: 10.1016/j.jaad.2020.06.1018. Epub 2020 Jul 3. J Am Acad Dermatol. 2020. PMID: 32622895 Free PMC article. No abstract available.
62 results